Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Palvella Therapeutics to post earnings of ($0.58) per share for the quarter.
Palvella Therapeutics Price Performance
Palvella Therapeutics stock opened at $27.87 on Tuesday. The firm has a market cap of $312.73 million, a price-to-earnings ratio of -2.30 and a beta of 0.54. The stock’s 50-day moving average is $19.08. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27.
Analysts Set New Price Targets
Several equities research analysts have commented on PVLA shares. TD Cowen initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price for the company. Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $39.00 target price on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Scotiabank began coverage on Palvella Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $42.75.
About Palvella Therapeutics
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- 3 Stocks to Consider Buying in October
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- What is an Earnings Surprise?
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
